Symbols

BNTX

BioNTech·NASDAQ

--(--)

BNTX fundamentals

BNTX Q4 2025 Earnings

BioNTech (BNTX) released its earnings on Mar 10, 2026: revenue was 1.06B (YoY -13.79%), beat estimates; EPS was -0.3862 (YoY -134.54%), missed estimates.

Revenue / YoY

1.06B

-13.79%

EPS / YoY

-0.3862

-134.54%

Report date

Mar 10, 2026

BNTX Earnings Call Summary for Q4,2025

Spin-off of mRNA Innovations: New independent company to focus on next-gen mRNA, with BioNTech retaining minority stake for collaboration potential.
Oncology Pipeline Momentum: 8 Phase III trials for Pumitamig expected by year-end, with 6 late-stage readouts in 2026.
Financial Discipline: 2025 R&D expenses down 2% YoY; 2026 guidance reflects focus on high-impact programs.
COVID-19 Vaccine Transition: Revenue decline expected as markets normalize, with U.S. competition and Europe seasonal demand driving trends.

Earnings

EPS

Revenue

Revenue & Expenses

BNTX has released its 2025 Q3 earnings report, with revenue of 1.78B, reflecting a YoY change of 28.48%, and net profit of -33.68M, showing a YoY change of -115.25%. The Sankey diagram below clearly presents BNTX's revenue sources and cost distribution.

Key Indicators

BioNTech (BNTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

BioNTech (BNTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

BioNTech (BNTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

BioNTech (BNTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown